Johanna Mercier's most recent trade in Gilead Sciences, Inc. was a trade of 3,000 Common Stock done at an average price of $141.0 . Disclosure was reported to the exchange on April 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Sale of securities on an exchange or to another person at price $ 140.96 per share. | 15 Apr 2026 | 3,000 | 128,779 (0%) | 0% | 141.0 | 422,880 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Sale of securities on an exchange or to another person at price $ 144.23 per share. | 16 Mar 2026 | 3,000 | 131,779 (0%) | 0% | 144.2 | 432,690 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 35,880 | 35,880 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 9,590 | 30,647 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 6,617 | 137,995 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 6,617 | 21,057 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.56 per share. | 10 Mar 2026 | 3,216 | 134,779 (0%) | 0% | 148.6 | 477,769 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 11,090 | 131,378 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 25,000 | 48,110 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 17 Feb 2026 | 25,000 | 148,288 (0%) | 0% | 66.6 | 1,666,000 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Sale of securities on an exchange or to another person at price $ 154.18 per share. | 17 Feb 2026 | 18,405 | 129,883 (0%) | 0% | 154.2 | 2,837,720 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Sale of securities on an exchange or to another person at price $ 154.91 per share. | 17 Feb 2026 | 9,395 | 120,488 (0%) | 0% | 154.9 | 1,455,384 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Sale of securities on an exchange or to another person at price $ 155.62 per share. | 17 Feb 2026 | 200 | 120,288 (0%) | 0% | 155.6 | 31,124 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 44,867 | 148,088 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Comm & Corp Aff Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.28 per share. | 03 Feb 2026 | 24,800 | 123,288 (0%) | 0% | 143.3 | 3,553,344 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 124.31 per share. | 15 Jan 2026 | 3,000 | 103,221 (0%) | 0% | 124.3 | 372,930 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 122.00 per share. | 15 Dec 2025 | 3,000 | 106,221 (0%) | 0% | 122 | 366,000 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 3,842 | 27,674 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 3,842 | 111,035 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.34 per share. | 10 Dec 2025 | 1,814 | 109,221 (0%) | 0% | 121.3 | 220,111 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 125.83 per share. | 17 Nov 2025 | 25,524 | 109,669 (0%) | 0% | 125.8 | 3,211,560 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 25,000 | 73,110 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 17 Nov 2025 | 25,000 | 135,193 (0%) | 0% | 66.6 | 1,666,000 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 126.26 per share. | 17 Nov 2025 | 2,476 | 107,193 (0%) | 0% | 126.3 | 312,614 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.08 per share. | 15 Oct 2025 | 3,000 | 110,193 (0%) | 0% | 118.1 | 354,240 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 113.57 per share. | 15 Sep 2025 | 3,000 | 113,193 (0%) | 0% | 113.6 | 340,710 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 3,844 | 118,012 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 3,844 | 31,516 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.25 per share. | 10 Sep 2025 | 1,819 | 116,193 (0%) | 0% | 115.3 | 209,640 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 11,800 | 98,810 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 11,800 | 111,310 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.51 per share. | 15 Aug 2025 | 11,800 | 117,168 (0%) | 0% | 118.5 | 1,398,405 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 15 Aug 2025 | 11,800 | 128,968 (0%) | 0% | 66.6 | 786,352 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.50 per share. | 15 Aug 2025 | 11,800 | 117,168 (0%) | 0% | 118.5 | 1,398,352 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 15 Aug 2025 | 11,800 | 128,968 (0%) | 0% | 66.6 | 786,352 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.51 per share. | 15 Aug 2025 | 2,800 | 114,368 (0%) | 0% | 118.5 | 331,821 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 700 | 98,110 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 700 | 110,610 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.97 per share. | 15 Aug 2025 | 700 | 117,168 (0%) | 0% | 119.0 | 83,278 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 15 Aug 2025 | 700 | 117,868 (0%) | 0% | 66.6 | 46,648 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.97 per share. | 15 Aug 2025 | 700 | 117,168 (0%) | 0% | 119.0 | 83,278 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 15 Aug 2025 | 700 | 117,868 (0%) | 0% | 66.6 | 46,648 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 118.96 per share. | 15 Aug 2025 | 200 | 114,168 (0%) | 0% | 119.0 | 23,793 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 111.03 per share. | 15 Jul 2025 | 3,000 | 117,168 (0%) | 0% | 111.0 | 333,090 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 110.17 per share. | 16 Jun 2025 | 3,000 | 120,168 (0%) | 0% | 110.2 | 330,510 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 3,843 | 124,995 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 3,843 | 35,360 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 1,827 | 123,168 (0%) | 0% | 110.1 | 201,134 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 22 May 2025 | 12,500 | 136,652 (0%) | 0% | 66.6 | 833,000 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2025 | 12,500 | 123,110 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2025 | 12,500 | 135,610 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 107.52 per share. | 22 May 2025 | 12,500 | 124,152 (0%) | 0% | 107.5 | 1,344,039 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.64 per share. | 22 May 2025 | 12,500 | 136,652 (0%) | 0% | 66.6 | 833,000 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 107.52 per share. | 22 May 2025 | 12,500 | 124,152 (0%) | 0% | 107.5 | 1,343,961 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 107.52 per share. | 22 May 2025 | 3,000 | 121,152 (0%) | 0% | 107.5 | 322,564 | Common Stock |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,318 | 3,318 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 1,435 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 1,435 | 3,535 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 49,020 | 49,020 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 11,090 | 39,203 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 8,080 | 28,113 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 8,080 | 128,059 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 3,907 | 124,152 (0%) | 0% | 117.2 | 457,939 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 70,712 | 165,645 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 45,666 | 119,979 (0%) | 0% | 98.0 | 4,474,811 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 19,793 | 94,933 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 3,752 | 36,193 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 3,752 | 76,879 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 1,739 | 75,140 (0%) | 0% | 92.3 | 160,579 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 91.28 per share. | 06 Nov 2024 | 5,000 | 73,127 (0%) | 0% | 91.3 | 456,400 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 84.23 per share. | 12 Sep 2024 | 15,925 | 91,559 (0%) | 0% | 84.2 | 1,341,363 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 83.25 per share. | 12 Sep 2024 | 13,432 | 78,127 (0%) | 0% | 83.3 | 1,118,214 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 3,752 | 39,945 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 3,752 | 109,218 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 1,734 | 107,484 (0%) | 0% | 81.4 | 141,217 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 78.03 per share. | 28 Aug 2024 | 9,513 | 105,466 (0%) | 0% | 78.0 | 742,299 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 73.98 per share. | 13 Aug 2024 | 5,490 | 114,979 (0%) | 0% | 74.0 | 406,150 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 3,751 | 122,183 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 3,751 | 43,697 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 1,714 | 120,469 (0%) | 0% | 65.3 | 111,839 | Common Stock |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,982 | 2,982 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,435 | 1,435 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Johanna Mercier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 2,100 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 87,970 | 87,970 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 17,305 | 47,448 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,819 | 30,143 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,819 | 122,991 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.12 per share. | 10 Mar 2024 | 4,559 | 118,432 (0%) | 0% | 75.1 | 342,472 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 3,025 | 116,172 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 3,025 | 36,962 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 53,969 | 135,656 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.26 per share. | 31 Jan 2024 | 22,509 | 113,147 (0%) | 0% | 78.3 | 1,761,554 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 20,086 | 81,687 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.23 per share. | 09 Jan 2024 | 8,242 | 82,729 (0%) | 0% | 85.2 | 702,466 | Common Stock |
| Gilead Sciences | Mercier Johanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 2,730 | 39,987 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Mercier Johanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 2,730 | 92,218 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.02 per share. | 10 Dec 2023 | 1,247 | 90,971 (0%) | 0% | 79.0 | 98,538 | Common Stock |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2023 | 2,730 | 42,717 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2023 | 2,730 | 90,744 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.00 per share. | 10 Sep 2023 | 1,256 | 89,488 (0%) | 0% | 76 | 95,456 | Common Stock |